We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
-11.01%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$645M
AUM Growth
+$36M
Cap. Flow
+$150M
Cap. Flow %
23.21%
Top 10 Hldgs %
72.39%
Holding
33
New
19
Increased
7
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$24.6M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$11.1M
3
EPIX
ESSA Pharma
EPIX
+$10.9M
4
EPZM
Epizyme, Inc
EPZM
+$9.97M
5
VSTM icon
Verastem
VSTM
+$8.65M

Top Sells

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$7.1M
2
ITOS
iTeos Therapeutics
ITOS
+$6.05M
3
RPTX
Repare Therapeutics
RPTX
+$1.17M

Sector Composition

Rank Sector Weight
1 Healthcare 94.65%
2 Miscellaneous 5.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$173M 26.78%
7,648,268
-265,619
-3% -$7.1M
ITOS
2
DELISTED
iTeos Therapeutics
ITOS
$56.9M 8.82%
2,107,092
-231,489
-10% -$6.05M
RPTX
3
DELISTED
Repare Therapeutics
RPTX
$43M 6.67%
1,639,849
-36,238
-2% -$1.17M
HOWL icon
4
Werewolf Therapeutics
HOWL
$45.8M
$41M 6.36%
2,388,011
– –
TCRR
5
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$28.7M 4.45%
3,370,982
– –
HARP
6
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$25.3M 3.92%
319,671
– –
ONCR
7
DELISTED
Oncorus, Inc.
ONCR
$22.2M 3.44%
2,377,031
– –
NTLA icon
8
Intellia Therapeutics
NTLA
$1.8B
$21.8M 3.38%
+162,620
New +$24.6M
MRUS
9
DELISTED
Merus
MRUS
$20.7M 3.21%
941,948
+241,069
+34% +$5.17M
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$20.3M 3.16%
3,972,830
+1,641,296
+70% +$9.97M
TPTX
11
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$18M 2.8%
271,350
+2,164
+0.8% +$154K
YMAB
12
DELISTED
Y-mAbs Therapeutics
YMAB
$12.9M 2.01%
452,970
+115,679
+34% +$3.65M
GTHX
13
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$11.5M 1.79%
860,502
+47,708
+6% +$777K
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$2.51B
$10.1M 1.57%
+704,767
New +$11.1M
ADCT icon
15
ADC Therapeutics
ADCT
$146M
$9.36M 1.45%
344,519
+126,492
+58% +$3.24M
CYTK icon
16
Cytokinetics
CYTK
$10B
$8.84M 1.37%
+247,291
New +$7.28M
VSTM icon
17
Verastem
VSTM
$654M
$8.7M 1.35%
+235,405
New +$8.65M
GERN icon
18
Geron
GERN
$970M
$7.85M 1.22%
+5,732,770
New +$7.65M
TVTX icon
19
Travere Therapeutics
TVTX
$6.19B
$7.43M 1.15%
+306,515
New +$5.63M
NEO icon
20
NeoGenomics
NEO
$2.32B
$7.21M 1.12%
+149,504
New +$6.92M
CRNX icon
21
Crinetics Pharmaceuticals
CRNX
$9B
$6.28M 0.97%
+298,392
New +$6.24M
MIRM icon
22
Mirum Pharmaceuticals
MIRM
$5.94B
$6.15M 0.95%
+308,532
New +$5.02M
HRMY icon
23
Harmony Biosciences
HRMY
$2.28B
$5.81M 0.9%
+151,650
New +$4.88M
EPIX
24
DELISTED
ESSA Pharma
EPIX
$5.47M 0.85%
+683,287
New +$10.9M
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
$5.22M 0.81%
+546,558
New +$5.59M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2021 Portfolio in Review

As of Q3 2021, MPM BioImpact held 33 positions worth $645M, up 5.9% from $609M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

MPM BioImpact deployed $150M of net new capital in Q3 2021, opening 19 new positions and adding to 7 existing holdings. Its largest new stake was Intellia Therapeutics: 162,620 shares worth $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Cullinan Oncology, an estimated $7.1M trimmed.

  • MPM BioImpact's largest Q3 2021 buy was Intellia Therapeutics: 162,620 shares worth $21.8M.
  • MPM BioImpact added most to Epizyme, Inc in Q3 2021, an estimated $9.97M increase.
  • MPM BioImpact's biggest Q3 2021 reduction was Cullinan Oncology, cutting an estimated $7.1M.
  • MPM BioImpact's ten largest holdings make up 72% of its $645M portfolio in Q3 2021.
  • MPM BioImpact opened 19 new positions and closed 0 in Q3 2021.
  • MPM BioImpact's portfolio value rose 5.9% quarter-over-quarter to $645M.

Based on MPM BioImpact's 13F filing for Q3 2021, filed 15 Nov 2021.